目的 建立多黏菌素B在重癥感染患者中的群體藥動學(xué)模型，為個體化給藥提供科學(xué)依據(jù)。方法 檢索PubMed、Embase、Web of Science、CNKI數(shù)據(jù)庫中關(guān)于靜脈滴注多黏菌素B的藥動學(xué)文獻(xiàn)，提取多黏菌素B在重癥感染患者中的藥動學(xué)數(shù)據(jù)，使用Monolix軟件建立多黏菌素B的群體藥動學(xué)模型，并對模型進(jìn)行圖形評價和Bootstrap法驗證。結(jié)果 多黏菌素B在重癥感染患者中的藥動學(xué)特性符合房室模型，多黏菌素B的清除率（CL）、中央室表觀分布容積（V1）、周邊室表觀分布容積（V2）、隔間清除率（Q）的群體典型值分別為4.36L/h、16.19L、35.14L、0.4L/h，患者的年齡對模型參數(shù)Q有顯著影響，模型評價表明模型穩(wěn)定，且有較好的預(yù)測效能。結(jié)論 本研究建立了重癥感染患者多黏菌素B的群體藥動學(xué)模型，可為多黏菌素B在成年重癥感染患者中的個體化用藥提供參考。

Objective To develop a population pharmacokinetics model of polymyxin B in patients with severe infection to provide scientific basis for individualized drug administration. Methods The literatures about the pharmacokinetics of polymyxin B were retrieved from PubMed, Embase, Web of Science, CNKI databases, and related pharmacokinetic data were collected from published clinical trials literatures. Then the population pharmacokinetics model of polymyxin B was constructed by Monolix, and the population pharmacokinetics model was validated by pattern evaluation and bootstrap method. Results The population pharmacokinetics characters of polymyxin B were best described by compartment model. The typical population values of CL, V1, V2, Q were 4.36 L/h, 16.19 L, 35.14 L, 0.4 L/h. Age of patients as a covariate affected the Q in this study. Model validation showed that the population pharmacokinetics model of polymyxin B established by this study was reliable and had good predictive performance. Conclusion The population pharmacokinetics model of polymyxin B in patients with severe infection is established successfully and could provide basis for the individualized dosage regimen in adult patients with severe infection.

R978.1

天津市醫(yī)學(xué)重點學(xué)科（專科）建設(shè)項目資助（TJYXZDXK-032A）；天津醫(yī)科大學(xué)朱憲彝紀(jì)念醫(yī)院院基金（ZXY-YJJ2020-8）